Innate Pharma SA (IPHYF) Financial Statements
Innate Pharma SA (IPHYF) files with the U.S. Securities and Exchange Commission under CIK 0001598599. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- 9.01 million EUR
- Net Income
- -49.18 million EUR
- Total Assets
- 62.72 million EUR
- Net Cash from Operations
- -52.76 million EUR
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Apr 1, 2026. Source: SEC filings (EDGAR XBRL). Amounts in EUR.
Open the full financial statements for IPHYF in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History